Also see: AutoZone, Cisco: Analysts' New RatingsEditor's Note: Green and red arrows refer to intraday stock price movement. NEW YORK ( TheStreet) -- STOCK COMMENTS / EPS CHANGES American Capital ( ACAS) estimates lowered at UBS through 2012. Pace of realizations slowing. Buy rating. AECOM Technology ( ACM - Get Report) estimates, target lowered at UBS. Shares of ACM now seen reaching $31. Estimates also lowered on valuation. Buy rating. AOL ( AOL) estimates, target lowered at Credit Suisse. Shares of AOL now seen reaching $15. Estimates also lowered on weak 2Q11 results. Neutral rating. Babcock & Wilcox ( BWC) numbers reduced at JP Morgan. BWC estimates were cut through 2012. Environmental spending has yet to ramp up. Neutral rating and new $28 price target. Babcock & Wilcox estimates, target lowered at UBS. Shares of BWC now seen reaching $23. Estimates also lowered to reflect a lower P/E multiple. Neutral rating. Cree ( CREE) estimates, target increased at UBS. Shares of CREE now seen reaching $32. Estimates also raised on improvements in LED demand. Neutral rating. CenturyLink ( CTL) estimates lowered at UBS through 2012. Shares provide an attractive entry point. Maintain $47 price target and Buy rating. Walt Disney ( DIS - Get Report) estimates cut at UBS. DIS estimates were lowered through 2012. Tougher comps and increases in sports rights costs. Maintain $42 price target and Neutral rating. ENSCO ( ESV) estimates, target lowered at UBS. Shares of ESV now seen reaching $62. Estimates also lowered on slightly higher operating expenses. Buy rating. General Motors ( GM - Get Report) estimates raised at Citigroup through 2012. Better operating outlook. Maintain $48 price target and Buy rating. Humana ( HUM) estimates increased at Morgan Stanley through 2013. Company is keeping a tight lid on costs. Equal-weight rating. MGM Resorts ( MGM - Get Report) estimates, target lowered at Citigroup. Shares of MGM now seen reaching $13.50. Estimates also lowered on macro concerns. Maintain Hold rating. Myriad Genetics ( MYGN) numbers cut at Goldman. Shares of MYGN now seen reaching $18. Estimates also lowered, as the company is realizing higher operating costs. Sell rating. Nuance Communications ( NUAN) target lowered at UBS to $24. Current macro uncertainties may not reward the stock. Maintain Buy rating.
Pfizer added to JPMorgan Analyst Focus List. $25 price target. Solid defensive play against the backdrop of a difficult market. SunPower ( SPWRA) estimates cut at Citigroup through 2012. ASP premium has compressed and pricing pressure remains. Maintain $16.50 price target and Hold rating. URS ( URS) estimates, target lowered at UBS. Shares of URS now seen reaching $38. Estimates also lowered on higher market risk premium. Neutral rating. Veeco Instruments ( VECO) estimates, target lowered at Citigroup. Shares of VECO now seen reaching $45. Estimates also lowered as price competition intensifies. ExxonMobil ( XOM) target lowered at Jefferies to $80. Downstream margins are vulnerable in the current environment, especially in Europe. Hold rating. End of report.